Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial. - Tate M; Illingworth CJR; MacGregor G; Cunningham L; Divers L; McCartney E; Paterson L; Kelly C; Shaw A; Perkins JS; Silva V; Holland P; et al. (Antimicrobial agents and chemotherapy, 2025)